Drugs for Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 61)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Thalidomide |
Approved, Investigational, Withdrawn |
Phase 2 |
|
50-35-1 |
5426 |
Synonyms:
(+-)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(+-)-THALIDOMIDE
(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(±)-THALIDOMIDE
1,3-DIOXO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE
2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE
3-PHTHALIMIDOGLUTARIMIDE
Algosediv
ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE
ALPHA-N-PHTHALYLGLUTARAMIDE
alpha-Phthalimidoglutarimide
Asidon 3
Asmadion
Asmaval
Bonbrain
Bonbrrin
Calmore
Calmorex
Celgene brand OF thalidomide
Contergan
Corronarobetin
Distaval
Distaxal
Distoval
Ectiluran
Enterosediv
Gastrinide
Glupan
Glutanon
Grippex
Hippuzon
Imida-Lab
Imidan
Imidene
Isomin
K-17
Kedavon
Kevadon
Lulamin
N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
Neaufatin
Neo
Neosedyn
Neosydyn
Nerosedyn
Neufatin
Neurodyn
Neurosedin
Neurosedym
Neurosedyn
Nevrodyn
Nibrol
Noctosediv
Noxodyn
|
N-Phthalimidoglutamic acid imide
N-Phthaloylglutamimide
N-Phthalylglutamic acid imide
N-PHTHALYL-GLUTAMINSAEURE-IMID
NSC-527179
NSC-66847
Pangul
Pantosediv
Poly-Giron
Polygripan
Predni-Sediv
Pro-ban M
Profarmil
Psycholiquid
Psychotablets
Quetimid
Quietoplex
Sandormin
Sedalis
Sedalis sedi-lab
Sedimide
Sedin
Sedisperil
Sedoval
Shin-naito S
Shinnibrol
Sleepan
Slipro
Softenil
Softenon
Talargan
TALIDEX
TALIDOMIDA
Talimol
Talismol
Telagan
Telargan
Telargean
Tensival
Thaled
Thalidomide
THALIDOMIDUM
Thalidomine usp26
Thalin
Thalinette
Thalomid
Theophilcholine
Valgis
Valgraine
Yodomin
Α-(N-PHTHALIMIDO)GLUTARIMIDE
Α-N-PHTHALYLGLUTARAMIDE
Α-PHTHALIMIDOGLUTARIMIDE
|
|
2 |
|
Zanubrutinib |
Approved, Investigational |
Phase 2 |
|
1691249-45-2 |
135565884 |
Synonyms:
(7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
7-(1-Acryloyl-4-piperidinyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide
BGB-3111
|
BGB-3111|BGB3111|Brukinsa®|compound 27b [US9447106]
Brukinsa
ZANUBRUTINIB
|
|
3 |
|
Dexamethasone acetate |
Approved, Investigational, Vet_approved |
Phase 2 |
|
1177-87-3 |
3680 |
Synonyms:
16alpha-Methyl-9alpha-fluoroprednisolone 21-acetate
2-{1-fluoro-14,17-dihydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethyl acetic acid
9alpha-Fluoro-16alpha-methylprednisolone acetate
DECADRON-LA
Dexamethasone 21-acetate
|
DEXAMETHASONE ACETATE
Dexamethasone acetate anhydrous
Dexamethasone acetate, anhydrous
Dexamethasone acetic acid
Dexamethasoni acetas
|
|
4 |
|
Dexamethasone |
Approved, Investigational, Vet_approved |
Phase 2 |
|
50-02-2 |
3003 5743 |
Synonyms:
[<sup>3</sup>H]-dexamethasone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16a-Methyl-9a-fluoro-1-dehydrocortisol
16Α-methyl-9α-fluoro-1-dehydrocortisol
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16a-methyl-9a-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
9a-Fluoro-16a-methylprednisolone
9a-Fluoro-16BETA-methylprednisolone
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-Fluoro-16alpha-methyl-prednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9Α-fluoro-16α-methylprednisolone
Adexone
Aeroseb-D
Aeroseb-dex
Ak dex OPH otic soln 0.1%
Alcon brand OF dexamethasone
alpha -Fluoro-16-alpha -methylcortisol
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (veterinary)
Bisu DS
Calonat
Corson
Corsone
Cortisumman
DALALONE
Decacort
Decacortin
Decaderm
Decadron
Decadron Tablets, Elixir
Decadron®|desametasone|fluormethylprednisolone
DECADRON-75
DECADRON-LA
Decagel
Decaject
Decaject l.a.
Decaject-l.a.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
DEX
DEXA
Dexa mamallet
DEXACEN-4
Dexacidin
Dexacort
Dexacortal
Dexa-cortidelt
Dexacortin
Dexa-cortisyl
DEXACORTISYL
Dexadeltone
Dexafarma
DEXAFREE
DEXAIR
Dexalona
Dexaltin
Dexa-Mamallet
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
DEXAMETHASONE
Dexaméthasone
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
DEXAMETHASONE METASULFOBENZOATE SODIUM
DEXAMETHASONE PALMITATE
Dexamethasone sodium phosphate
|
DEXAMETHASONE VALERATE
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexa-scheroson
Dexa-sine
Dexason
Dexasone
Dexasone 0.5MG
Dexasone 0.75MG
Dexasone 4MG
Dexasporin
Dex-ide
Dexinolon
Dexinoral
Dexone
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
Dexonium
Dexpak
DEXSOL
Dextelan
DEXTENZA
DEXYCU KIT
Dezone
Dinormon
DROPODEX
DXM
DXM833
DXMS
ECR brand OF dexamethasone
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy brand OF dexamethasone
Gammacorten
GPPE EAR SPY
Hexadecadrol
Hexadrol
Hexadrol elixir
Hexadrol Tablets
HL-Dex
ICN brand OF dexamethasone
IontoDex
Isopto-dex
ISV-305
KORTICO INJECTION
Lokalison F
Loverine
Luxazone
MARTAPAN
Maxidex
Maxidex ont 0.1%
Maxidex sus 0.1%
Maxitrol
Mediamethasone
Merck brand OF dexamethasone
Merz brand 1 OF dexamethasone
Merz brand 2 OF dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
Mymethasone
Naquasone (veterinary)
NEODECADRON
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
NSC 34521
NSC-34521
Ocu-trol
Oradexon
OTO-104
OTOMIZE
OZURDEX
Pet derm III
Pet-Derm Iii
PHL-Dexamethasone
PMS Dexamethasone elixir 0.5mg/5ML
PMS-Dexamethasone
Policort
Posurdex
Prednisolon F
Prednisolone F
Prodex
Sandoz dexamethasone
SK-Dexamethasone
SOFRADEX
SPERSADEX COMP
Spoloven
Sunia sol D
Superprednol
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
Visumetazone
|
|
5 |
|
Zidovudine |
Approved |
Phase 2 |
|
30516-87-1 |
35370 |
Synonyms:
3' Azido 2',3' dideoxythymidine
3' Azido 3' deoxythymidine
3'-Azido-2',3'-dideoxythymidine
3'-Azido-3'-deoxythymidine
Antiviral azt
Apo-Zidovudine
Azidothymidine
AZT
AZT (antiviral)
AZT antiviral
AZT, antiviral
Aztec
BW a509U
BWA 509u
BWA509u
|
BWA-509u
BW-A509U
BW-A-509U
COMPOUND S
COMPOUND-S
Novo-Azt
NSC-602670
Retrovir
ZDV
Zidovudin
Zidovudina
Zidovudine
Zidovudine EP III
Zidovudinum
|
|
6 |
|
Sirolimus |
Approved, Investigational |
Phase 2 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
7 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
8 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 2 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
9 |
|
Lenograstim |
Approved, Investigational |
Phase 2 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
10 |
|
Bortezomib |
Approved, Investigational |
Phase 2 |
|
179324-69-7 |
387447 93860 |
Synonyms:
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID
341, PS
BORTEZOMIB
BORTEZOMIB HYDRATE
LDP 341
LDP-341
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
|
NSC-681239
PEPTIDE BORONATE
peptide boronate|PS-341|Velcade®
PS 341
PS-341
Velcade
|
|
11 |
|
Ganciclovir |
Approved, Investigational |
Phase 2 |
|
82410-32-0 |
3454 |
Synonyms:
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-Amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-Amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-Amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-(1,3-DIHYDROXY-propoxymethane)guanine
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
BIOLF-62
BW-759U
CYMEVENE
|
Cytovene
GA2
GANCICLOVIR
Ganciclovir sodium
Ganciclovir, monosodium salt
Ganciclovirum
Gancyclovir
RS-21592
VIRGAN
Vitrasert
Zirgan
|
|
12 |
|
Siltuximab |
Approved, Investigational |
Phase 2 |
|
541502-14-1 |
|
Synonyms:
|
13 |
|
Suramin |
Investigational |
Phase 2 |
|
129-46-4, 145-63-1 |
5361 |
Synonyms:
8,8'-[CARBONYLBIS[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonate
8,8'-[CARBONYLBIS[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonIC ACID
8,8'-[CARBONYLBIS[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulphonate
8,8'-[CARBONYLBIS[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulphonic acid
Bayer 205
Belganyl
CI-1003
CI-1003|suramine
Hexasodium salt suramin
Monosodium salt suramin
Moranil
Naganin
Naganol
|
Naphuride
NSC-34936
Salt suramin, hexasodium
Salt suramin, monosodium
Sodium suramin
Sodium, suramin
SURAMIN
Suramin sodium
Suramin, hexasodium salt
Suramin, monosodium salt
Suramine
SVR
|
|
14 |
|
Analgesics |
|
Phase 2 |
|
|
|
15 |
|
Antipyretics |
|
Phase 2 |
|
|
|
16 |
|
Histamine H1 Antagonists |
|
Phase 2 |
|
|
|
17 |
|
Histamine Antagonists |
|
Phase 2 |
|
|
|
18 |
|
Antiprotozoal Agents |
|
Phase 2 |
|
|
|
19 |
|
Anthelmintics |
|
Phase 2 |
|
|
|
20 |
|
Antiparasitic Agents |
|
Phase 2 |
|
|
|
21 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
22 |
|
Chrysarobin |
|
Phase 2 |
|
|
|
23 |
|
Immunoglobulins, Intravenous |
|
Phase 2 |
|
|
|
24 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
25 |
|
Anti-Retroviral Agents |
|
Phase 2 |
|
|
|
26 |
|
Anti-HIV Agents |
|
Phase 2 |
|
|
|
27 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
28 |
|
Reverse Transcriptase Inhibitors |
|
Phase 2 |
|
|
|
29 |
|
Antifungal Agents |
|
Phase 2 |
|
|
|
30 |
|
interferons |
|
Phase 2 |
|
|
|
31 |
|
Interferon-alpha |
|
Phase 2 |
|
|
|
32 |
|
Ganciclovir triphosphate |
|
Phase 2 |
|
|
|
33 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
34 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
35 |
|
Antibodies |
|
Phase 2 |
|
|
|
36 |
|
Picropodophyllin |
Approved, Investigational |
Phase 1 |
|
518-28-5, 477-47-4 |
10607 72435 |
Synonyms:
(−)-podophyllotoxin
(-)-Podophyllotoxin
6,7]NAPHTHO[2,3-D][1,3]DIOXOL-6(5AH)-ONE
9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDROFURO[3',4'
9-HYDROXY-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-D][1,3]dioxol-6(5ah)-one
Ardern brand OF podophyllotoxin
AXL-1717
AXL1717|podofilox
Canderm brand OF podophyllotoxin
Condyline
Condylox
CPH86
Epipodophyllotoxin
Fides ecopharma brand OF podophyllotoxin
Hamilton brand OF podophyllotoxin
Newport brand OF podophyllotoxin
NSC-24818
NSC-36407
Oclassen brand OF podophyllotoxin
Paddock brand OF podophyllotoxin
Paladin brand OF podophyllotoxin
|
PICROPODOPHYLLIN
PICROPODOPHYLLOTOXIN
PODOCON-25
Podofilm
Podofilox
Podophyllinate lactone
Podophyllinic acid lactone
Podophyllotoxin
Podophyllotoxin 7
PODOPHYLLOTOXIN PICROPODOPHYLLIN
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-isomer
PPT
Stiefel brand OF podophyllotoxin
Wartec
Warticon
Wolff brand OF podophyllotoxin
Yamanouchi brand OF podophyllotoxin
|
|
37 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 1 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
38 |
|
Methotrexate |
Approved |
Phase 1 |
|
1959-05-2, 59-05-2 |
4112 126941 |
Synonyms:
[<sup>3</sup>H]-methotrexate
2-[(4-{[(4-amino-2-imino-2,3-dihydropteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioate
4-Amino-10-methylfolate
4-Amino-10-methylfolic acid
4-Amino-N(10)-methylpteroylglutamate
4-Amino-N(10)-methylpteroylglutamic acid
ABITREXATE
Abitrexate®|amethopterin|Nordimet®|Rasuvo®
Amethopterin
Amethopterine
Antifolan
Arbitrexate
CL-14377
Dicesium salt methotrexate
EBETREX
EMT-25299
Emtexate
EMTEXATE HIGH-POT
EMTEXATE PF
Emtexic acid
FOLEX
HDMTX
Hydrate, methotrexate
L-Amethopterin
Ledertrexate
Ledertrexic acid
MAXTREX
Metatrexan
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate
Méthotrexate
Methotrexate hydrate
|
Methotrexate sodium
Methotrexate, (D)-isomer
Methotrexate, (DL)-isomer
Methotrexate, dicesium salt
Methotrexate, disodium salt
Methotrexate, sodium salt
Methotrexatum
Methotrexic acid
Methylaminopterin
Methylaminopterinum
METOJECT
Metotrexato
Mexate
MEXATE-AQ
MTX
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamate
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-Bismethylpteroylglutamic acid
NSC-740
Otrexup
OTREXUP PFS
R-9985
RASUVO
Rheumatrex
R-METHOTREXATE
Sodium, methotrexate
TCMDC-123832
TCMDC-125488
TCMDC-125858
TCMDC-125858TCMDC-125488TCMDC-123832Methotrexate
TCMDC-125858TCMDC-125488TCMDC-123832Methotrexic acid
Trexall
Xatmep
ZLATAL
|
|
39 |
|
Daunorubicin |
Approved |
Phase 1 |
|
20830-81-3 |
30323 |
Synonyms:
(+)-Daunomycin
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
Acetyladriamycin
Anthracyline
Antibiotics From Streptomyces Coeruleorubidus
Cerubidin
Cerubidine
Daunamycin
Daunarubicinum
Dauno rubidomycine
Daunoblastin
Daunoblastine
Daunomycin
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
DAUNORUBICIN
Daunorubicin Hcl
Daunorubicin hydrochloride
Daunorubicin, Hydrochloride
DAUNORUBICINA
|
DAUNORUBICINE
Daunorubicinum
Daunorubicinum [INN-Latin]
Dauno-rubidomycine
DaunoXome
DM
DM1
FI 6339
FI-6339
Hydrochloride, daunorubicin
Leukaemomycin C
NDC-0082-4155
NSC-83142
Ondena
Rcra Waste No. U059
RP 13057
Rp 13057 Hydrochloride
RP-13057
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
VALRUBICIN IMPURITY, DAUNORUBICIN
|
|
40 |
|
Cetuximab |
Approved |
Phase 1 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
41 |
|
Valproic acid |
Approved, Investigational |
Phase 1 |
|
99-66-1 |
3121 |
Synonyms:
(N-C3H7)2chcooh
(S)-2-Propyl-4-pentanoate
(S)-2-Propyl-4-pentanoic acid
2 Propylpentanoic acid
2-N-PROPYL-4-PENTENOIC ACID
2-N-Propyl-N-valerate
2-N-Propyl-N-valeric acid
2-Propylpentanoate
2-PROPYL-pentanoate
2-Propylpentanoic acid
2-PROPYL-pentanoIC ACID
2-Propylvalerate
2-Propylvaleric acid
44089
4-Heptanecarboxylate
4-Heptanecarboxylic acid
A-44090
A-44090|Depakote®|Epilim®|valproate sodium
Acetate, dipropyl
Acid, propylisopropylacetic
Acid, valproic
Acide valproique
acide valproïque
Acido valproico
ácido valproico
Acidum valproicum
Alti-valproic
Apo-divalproex
Apo-valproic
Apo-valproic syrup
Avugane
Baceca
Calcium valproate
Calcium, valproate
Convulex
Convulsofin
Delepsine
Depacon
Depakene
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Deproic
Di-N-propylacetate
Di-N-propylacetic acid
Di-N-propylessigsaeure
Di-N-propylessigsaure
Di-n-propylessigsäure
Dipropyl acetate
Dipropylacetate
Dipropylacetic acid
Divalproex
Divalproex sodium
DOM-divalproex
Dom-valproate
DOM-valproic
Dom-valproic acid
DOM-valproic acid e.c.
Dom-valproic acid syrup
DPA
Epiject i.v.
Epilex
Epilim
|
Epival
Epival er
Ergenyl
Gen-divalproex
Kyselina 2-propylvalerova
LEP321
Magnesium valproate
Med valproic
Mylproin
Myproate
Myproic acid
N-Dipropylacetic acid
N-DPA
Novo-divalproex
Novo-valproic
Novo-valproic - ecc
Novo-valproic soft gel cap
NSC-93819
Nu-valproic
PEAC
Penta-valproic
PHL-Valproate
PHL-Valproic acid
PHL-Valproic acid e.c.
PMS-Divalproex
PMS-Valproate
PMS-Valproic acid
PMS-Valproic acid e.c.
Propylisopropylacetic acid
Propylvaleric acid
Ratio-valproic - ecc
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
Sandoz valproic
Savicol
Semisodium valproate
Sodium hydrogen divalproate
Sodium valproate
Sodium, divalproex
Sodium, valproate
Sprinkle
STAVZOR
Valcote
Valparin
Valproate
Valproate calcium
Valproate semisodique [French]
Valproate semisodium
Valproate sodium
Valproate, calcium
Valproate, magnesium
Valproate, semisodium
Valproate, sodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
VALPROIC ACID
Valproic acid usp
Valproic acid USP24
Valproic acid, sodium salt (2:1)
Valproinsaeure
Valproinsäure
VPA
Vupral
|
|
42 |
|
Bevacizumab |
Approved, Investigational |
Phase 1 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
43 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 1 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
44 |
|
Folic Acid Antagonists |
|
Phase 1 |
|
|
|
45 |
|
Folate |
|
Phase 1 |
|
|
|
46 |
|
Vitamin B9 |
|
Phase 1 |
|
|
|
47 |
|
Keratolytic Agents |
|
Phase 1 |
|
|
|
48 |
|
Vitamin B Complex |
|
Phase 1 |
|
|
|
49 |
|
Dermatologic Agents |
|
Phase 1 |
|
|
|
50 |
|
Neurotransmitter Agents |
|
Phase 1 |
|
|
|
Interventional clinical trials:
(show all 35)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Clinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to Valganciclovir |
Withdrawn |
NCT00361933 |
Phase 4 |
Valganciclovir |
2 |
Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot Trial |
Unknown status |
NCT03043105 |
Phase 2 |
Thalidomide, cyclophosphamide and prednisone |
3 |
Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease |
Completed |
NCT01441063 |
Phase 2 |
Zidovudine;Tocilizumab;Valganciclovir (VGC) |
4 |
A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman's Disease |
Completed |
NCT01024036 |
Phase 2 |
Siltuximab;Placebo;Best Supportive Care (BSC) |
5 |
A PHASE II PILOT STUDY OF SURAMIN IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA AND PATIENTS WITH CASTLEMAN'S DISEASE |
Completed |
NCT00002652 |
Phase 2 |
suramin |
6 |
An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's Disease |
Completed |
NCT01400503 |
Phase 2 |
Siltuximab |
7 |
LCCC 1950 - Rituximab for Multicentric Castleman Disease in Malawi, A Single-Arm Phase II Safety/Efficacy Trial |
Recruiting |
NCT04585893 |
Phase 2 |
Rituximab;Etoposide |
8 |
The Efficacy and Safety of Zanuburutinib in Relapsed and Refractory Idiopathic Multicentric Castleman Disease (iMCD): a Prospective, Single-center, Single-arm Trial |
Recruiting |
NCT04743687 |
Phase 2 |
Zanubrutinib |
9 |
A Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease |
Recruiting |
NCT03933904 |
Phase 2 |
Sirolimus |
10 |
A Single-arm, Open-label, Multi-center Phase â…¡a Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-IL-6R mAb Injection in the Treatment of Patients With Idiopathic Multicentric Castleman's Disease |
Recruiting |
NCT05345522 |
Phase 2 |
|
11 |
Bortezomib, Cyclophosphamide and Dexamethasone (BCD) in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) : a Prospective, Single-center, Single-arm, Phase-II Pilot Trial |
Recruiting |
NCT03982771 |
Phase 2 |
Bortezomib;Cyclophosphamide;Dexamethason |
12 |
Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity |
Active, not recruiting |
NCT00092222 |
Phase 2 |
Etoposide;Interferon-alpha;Rituximab;Zidovudine;Liposomal Doxorubicin;Bortezomib;Valganciclovir;Doxorubicin;Vincristine;Cyclophosphamide;Filgrastim (G-CSF);Prednisone;Sirolimus |
13 |
A Phase 2 Study of Intrapatient Siltuximab Dose Escalation in Patients With Idiopathic Multicentric Castleman Disease That Has Progressed After Prior Siltuximab Treatment |
Terminated |
NCT04838860 |
Phase 2 |
Siltuximab |
14 |
Multicenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB) |
Terminated |
NCT00127569 |
Phase 2 |
Rituximab |
15 |
Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease) |
Withdrawn |
NCT02228512 |
Phase 1, Phase 2 |
Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide |
16 |
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma |
Unknown status |
NCT00891280 |
Phase 1 |
CX-4945 oral formulation |
17 |
A Phase 1 Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease |
Completed |
NCT00412321 |
Phase 1 |
CNTO 328 |
18 |
Provision of Tocilizumab for Patients With Multicentric Castleman's Disease Who Have Demonstrated Benefit From Previous Tocilizumab Treatment |
Completed |
NCT01183598 |
Phase 1 |
tocilizumab [RoActemra/Actemra] |
19 |
A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in Uganda |
Recruiting |
NCT03864419 |
Phase 1 |
Cyclophosphamide;Vincristine;Methotrexate;Doxorubicin;Doxorubicin Hydrochloride;Prednisone;Etoposide |
20 |
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications |
Active, not recruiting |
NCT01552434 |
Phase 1 |
Temsirolimus;Valproic Acid |
21 |
Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma |
Terminated |
NCT02109224 |
Phase 1 |
Ibrutinib |
22 |
Castleman Disease - Diagnosis and Surgery |
Completed |
NCT05440305 |
|
|
23 |
Unlock the Cell: Intracellular Inflammatory Pathways and Flow Cytometry Study for Castleman's Disease |
Completed |
NCT02853968 |
|
|
24 |
Epithelioid Hemangioma of Bone And Soft Tissue: a Benign Tumor With Metastatic Potential |
Completed |
NCT03169595 |
|
|
25 |
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease |
Recruiting |
NCT03300830 |
|
|
26 |
ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease |
Recruiting |
NCT02817997 |
|
|
27 |
Exploratory Analysis of the Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease |
Recruiting |
NCT05028621 |
|
|
28 |
Screening for HHV8 Infection in Solid Organ Transplantation Donors, Candidates and Recipients |
Recruiting |
NCT05081141 |
|
|
29 |
Registry for Adults With Plasma Cell Disorders (PCD's) |
Recruiting |
NCT03717844 |
|
|
30 |
A Prospective Cohort Study of Patients With Plasma Cell Disorders (PCDs) in PKUFH |
Recruiting |
NCT05283993 |
|
|
31 |
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer |
Recruiting |
NCT00006518 |
|
|
32 |
Natural History Study of KSHV-Associated Multicentric Castleman's Disease |
Recruiting |
NCT04968288 |
|
|
33 |
Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis |
Active, not recruiting |
NCT04742387 |
|
|
34 |
A Pilot Trial of Nelfinavir for the Lytic Activation and Treatment of Gammaherpesvirus-Related Tumors |
Terminated |
NCT02080416 |
Early Phase 1 |
Nelfinavir |
35 |
The Castleman Disease Collaborative Network Biobank: A Collection of Biospecimens and Clinical Data to Facilitate Research |
Withdrawn |
NCT02871050 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
|